|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Jason_Coloma
|
|
gptkbp:clinicalTrialPhase
|
gptkb:MAZE-001_Phase_1
|
|
gptkbp:focusesOn
|
genetic diseases
|
|
gptkbp:foundedYear
|
2018
|
|
gptkbp:founder
|
gptkb:Robert_Nelsen
gptkb:Vikram_Bajaj
gptkb:Foresite_Capital
gptkb:Arch_Venture_Partners
gptkb:Alexandria_Venture_Investments
gptkb:Casdin_Capital
gptkb:David_Schenkein
gptkb:Third_Rock_Ventures
gptkb:Eric_Green
gptkb:Mark_Fishman
gptkb:Charles_Homcy
gptkb:James_Sabry
GV (formerly Google Ventures)
|
|
gptkbp:hasProductPipeline
|
gptkb:MAZE-001
gptkb:MAZE-002
gptkb:MAZE-003
|
|
gptkbp:hasRaisedFunding
|
$191 million
|
|
gptkbp:headquartersLocation
|
gptkb:South_San_Francisco,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Maze Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:keyPerson
|
gptkb:Robert_Nelsen
gptkb:Vikram_Bajaj
gptkb:Foresite_Capital
gptkb:Arch_Venture_Partners
gptkb:Alexandria_Venture_Investments
gptkb:Casdin_Capital
gptkb:David_Schenkein
gptkb:Third_Rock_Ventures
gptkb:Eric_Green
gptkb:Mark_Fishman
gptkb:Charles_Homcy
gptkb:James_Sabry
gptkb:Jason_Coloma
GV (formerly Google Ventures)
|
|
gptkbp:mission
|
transform the lives of patients through the understanding of genetic modifiers
|
|
gptkbp:specializesIn
|
genomics
precision medicine
drug discovery
|
|
gptkbp:technology
|
data science
functional genomics
human genetic modifiers
|
|
gptkbp:therapeuticArea
|
rare diseases
common diseases
|
|
gptkbp:website
|
https://mazetx.com/
|
|
gptkbp:bfsParent
|
gptkb:Alexandria_Venture_Investments
gptkb:Laura_Deming
|
|
gptkbp:bfsLayer
|
6
|